Impact of Lofexidine on Stress, Craving and Opioid Use
Status:
Recruiting
Trial end date:
2023-07-31
Target enrollment:
Participant gender:
Summary
Individuals with opioid use disorder who are stabilized on buprenorphine or methadone will be
randomly assigned to receive placebo or lofexidine for 5 weeks. At the end of five weeks,
they will complete a human laboratory stress task and scripted opioid imagery task.
Throughout the study a CREMA app (Cue Reactivity Ecological Momentary Assessment) will be
used to monitor stress, craving and use in the natural environment.
Phase:
Phase 2
Details
Lead Sponsor:
Medical University of South Carolina
Collaborators:
National Institute on Drug Abuse (NIDA) National Institutes of Health (NIH)